Structure-based computational screening of cyclotides as putative CYP19A1-binding scaffolds for modulation of estrogen biosynthesis in adenomyosis
Other
OA: gold
public-domain-us
Abstract
Adenomyosis is a chronic estrogen-dependent gynecological disorder associated with dysmenorrhea, abnormal uterine bleeding, chronic pelvic pain, infertility, and recurrent implantation failure. Because human placental aromatase cytochrome P450 (CYP19A1) plays a central role in local estrogen biosynthesis, this study employed an integrated in silico workflow to identify cyclotide scaffolds capable of interacting with CYP19A1. The receptor structure was prepared and validated, while protein-protein interaction analysis confirmed its involvement in steroidogenesis and estrogen biosynthesis. Twenty cyclotides were modeled and screened against the predicted active site of CYP19A1. Based on an integrated evaluation of HADDOCK and ClusPro docking, binding orientation, and interaction characteristics, cycloviolacin O4 was prioritized as the lead candidate. The predicted CYP19A1-cycloviolacin O4 complex exhibited a HADDOCK score of -82.8 ± 9.8, a cluster RMSD of 0.2 ± 0.1 Å, and a ClusPro energy score of -872.1. Docking against the reference inhibitor exemestane and the reference peptide SNA-60-367-10 provided additional computational benchmarking. Subsequent 500 ns molecular dynamics simulations, normal mode analysis, and MM-GBSA/MM-PBSA calculations supported the predicted structural stability and dynamic compatibility of the complex, yielding binding free energies of -66.58 ± 3.46 kcal/mol (MM-GBSA) and -4.56 ± 4.29 kcal/mol (MM-PBSA). Computational safety assessment predicted cycloviolacin O4 to be non-antigenic, non-allergenic, and non-toxic, while immune simulation suggested a balanced immune response. Collectively, these findings identify cycloviolacin O4 as a computationally predicted CYP19A1-binding cyclotide scaffold. However, these observations are derived exclusively from computational analyses and require biochemical, cellular, and in vivo validation before any conclusions regarding biological activity or therapeutic potential can be drawn.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (48)
- Adenomyosis: Mechanisms and Pathogenesis via openalex
- Current and Future Medical Treatment of Adenomyosis via openalex
- Epidemiology of Adenomyosis via openalex
- Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium via openalex
- Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial via openalex
- Mechanisms and Pathogenesis of Adenomyosis via openalex
- W2098276724 via openalex
- W2102367710 via openalex
- W2113121895 via openalex
- W2144857097 via openalex
- W2152065574 via openalex
- W2160645542 via openalex
- W2404999034 via openalex
- W2572080171 via openalex
- W2736858912 via openalex
- W2766078662 via openalex
- W2770320302 via openalex
- W2950200056 via openalex
- W3142080073 via openalex
- W3155998226 via openalex
- W4210564571 via openalex
- W4286697411 via openalex
- W4296295845 via openalex
- W4297988259 via openalex
- W4303981572 via openalex
- W4310525961 via openalex
- W4324370650 via openalex
- W4384502106 via openalex
- W4388870365 via openalex
- W4389476429 via openalex
- W4390267891 via openalex
- W4399294776 via openalex
- W4402170422 via openalex
- W4403259546 via openalex
- W4406721948 via openalex
- W4407366169 via openalex
- W4409648280 via openalex
- W4409666513 via openalex
- W4412161018 via openalex
- W4416392989 via openalex
- W7128586163 via openalex
- W1925466818 via openalex
- W7135198003 via openalex
- W2027067039 via openalex
- W2053538195 via openalex
- W2055117214 via openalex
- W2078584334 via openalex
- W2081912151 via openalex
Source provenance
- europepmc
- last seen: 2026-11-19T06:13:19.037553+00:00
- openalex
- last seen: 2026-11-19T06:04:33.792782+00:00
- pubmed
- last seen: 2026-11-19T06:06:24.241706+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine